Biocon Biologics
Kathy Skoglund has a vast experience in the pharmaceutical industry, starting from their role as a Sr. Executive in Glaxo to their current position as Head of US National Accounts at Biocon Biologics. Kathy has successfully managed and built teams, negotiated contracts, and developed relationships with major health systems and GPOs throughout their career. Kathy's educational background includes a BSE in Chemical Engineering from Arizona State University and a dual Master's degree in MBA and MHA from the University of Maryland Global Campus.
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics